Table 4.
Characteristic | Vehicle | CMG-1X | CMG-5X | Trend Analysis |
---|---|---|---|---|
Initial BW (g) | 37.2.6 ± 1.0 | 37.3 ± 1.3 | 37.8 ± 1.7 | 0.2231 |
Final BW (g) | 38.5 ± 1.5 | 38.9 ± 0.9 | 38.6 ± 1.3 | 0.7732 |
Food intake (g/day) | 7.3 ± 0.6 | 7.2 ± 0.7 | 7.2 ± 0.3 | 0.8104 |
Water intake (mL/day) | 8.5 ± 0.6 | 8.6 ± 0.5 | 8.3 ± 0.3 | 0.1808 |
Liver (g) | 2.09 ± 0.16 | 2.10 ± 0.10 | 2.08 ± 0.14 | 08814 |
Kidney (g) | 0.60 ± 0.05 | 0.60 ± 0.03 | 0.61 ± 0.05 | 0.7797 |
Heart (g) | 0.26 ± 0.04 | 0.27 ± 0.03 | 0.27 ± 0.04 | 0.4513 |
Lung (g) | 0.22 ± 0.02 | 0.22 ± 0.01 | 0.22 ± 0.02 | 0.9438 |
Muscle (g) | 0.37 ± 0.02 a | 0.39 ± 0.01 b | 0.40 ± 0.01 b | <0.0001 (↑) |
EFP (g) | 0.33 ± 0.15 | 0.31 ± 0.01 | 0.29 ± 0.01 | 0.8270 |
BAT (g) | 0.076 ± 0.011 a | 0.090 ± 0.006 b | 0.095 ± 0.009 b | <0.0001 (↑) |
Relative liver weight (%) | 5.43 ± 0.32 | 5.40 ± 0.30 | 5.38 ± 0.22 | 0.8766 |
Relative kidney weight (%) | 1.56 ± 0.11 | 1.55 ± 0.08 | 1.57 ± 0.13 | 0.9078 |
Relative Heart weight (%) | 0.67 ± 0.10 | 0.70 ± 0.08 | 0.69 ± 0.10 | 0.4836 |
Relative Lung weight (%) | 0.58 ± 0.05 | 0.56 ± 0.03 | 0.58 ± 0.05 | 1.0000 |
Relative Muscle weight (%) | 0.95 ± 0.05 a | 1.01 ± 0.03 b | 1.03 ± 0.05 b | 0.0004 (↑) |
Relative EFP weight (%) | 0.85 ± 0.37 | 0.79 ± 0.18 | 0.76 ± 0.20 | 0.8081 |
Relative BAT weight (%) | 0.20 ± 0.03 a | 0.23 ± 0.02 b | 0.25 ± 0.03 b | <0.0001 (↑) |
Data are mean ± SD, n = 8 mice/group. Values in the same line with different superscripts letters (a, b) differ significantly, p < 0.05 by one-way ANOVA. Food efficiency ratio: body weight (BW) gain (g/day)/food intake (g/day). Muscle mass includes both gastrocnemius and soleus muscles in the lower legs. BAT: brown adipose tissue; EFP: epididymal fat pad. Mice were pretreated with vehicle, CMG-1X, or CMG-5X for 4 weeks. The arrows up mean dose-dependently increase by CMG supplementation.